Sphingosine 1-Phosphate Receptor-Targeted Therapeutics in Rheumatic Diseases

The authors review the potential of sphingosine 1-phosphate receptor modulators for the treatment of systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis and summarize the rationale, pathobiology and evidence from preclinical models and clinical studies.